7月23日，创新药板块盘中异动拉升，益诺思开盘后一度大涨超15%，截至发稿换手率达13.70%，成交 额突破1.61亿元。此次异动与政策面利好及公司基本面改善密切相关。 消息面上，江海证券指出，国家医保局明确"新药不集采、集采非新药"原则，有效化解市场对创新药纳 入集采的担忧，为产业注入稳定政策预期。规则明确后，创新药企业研发投入积极性有望提升，推动行 业从"政策扰动期"迈向"规则明确期"。 非临床安评行业壁垒较高，GLP认证是核心门槛(实验室建设周期长、认证繁琐、固定资产投入大)，国 内资源稀缺。截至2023年底，仅六家CRO企业(含益诺思)和两家科研院所通过NMPA、OECD及FDA三 大监管机构GLP认证。国内药企安评业务外包渗透率达70%，益诺思凭借覆盖全球三大监管要求的资 质、丰富项目经验及优质试验设施(如动物房)形成竞争优势。 当前创新药产业链景气度回升：政策端医保支付向创新药倾斜，地方提供资金支持；投融资端大型药企 研发投入稳定，Biotech融资企稳；2025年上半年国产创新药海外授权(BD)交易总额接近去年全年，既 体现国际认可，也通过首付款、里程碑款缓解企业资金压力。CRO主流企业订单充裕 ...

Core Viewpoint - Yinosh successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, becoming the first central enterprise CRO in China, highlighting its leadership in the non-clinical research service sector and its significant market share in non-clinical safety evaluation [1][2]. Company Performance - In 2024, Yinosh achieved a revenue of 1.142 billion yuan, a year-on-year growth of 9.94%, with non-clinical CRO business revenue exceeding 1 billion yuan [2]. - The company reported a net profit of 148 million yuan, with a non-recurring net profit of 125 million yuan [2]. - The non-clinical CRO business generated 1.089 billion yuan in revenue, growing by 8.99%, while the clinical CRO business saw a revenue increase of 27.17%, reaching 46.9385 million yuan [2]. Strategic Focus - Yinosh emphasizes a customer-centric approach and focuses on core business areas, enhancing its competitive edge through innovation and reform [1][3]. - The company is expanding its laboratory scale and introducing advanced equipment, supported by the broadened financing channels post-listing [2]. R&D Investment - Yinosh has consistently increased its R&D investment, reaching 60.5325 million yuan in 2024, reflecting its commitment to scientific leadership [3][4]. Market Positioning - The company is positioned as a leader in non-clinical safety evaluation, providing solutions for emerging drug development directions, including multi-specific antibodies and gene therapies [4][5]. - Yinosh has established a differentiated competitive advantage through unique service platforms and customized solutions tailored to specific drug characteristics [5]. Global Strategy - Yinosh is actively pursuing a global strategy, with a focus on international collaboration and market expansion, aiming to enhance its service capabilities and contribute to global health [6]. - The company anticipates a significant increase in the number of innovative drug candidates sourced from China, projecting that this could exceed 50% in the near future [6].

Core Viewpoint - The company, Zhaoyan New Drug, has experienced a decline in stock price and revenue, while showing significant growth in net profit, indicating mixed performance in the current market environment [1]. Company Summary - Zhaoyan New Drug's closing stock price on July 2 was 21.95 yuan, down 1.57%, with a rolling PE ratio of 42.46 times and a total market capitalization of 16.451 billion yuan [1]. - The company operates primarily in non-clinical safety evaluation services for drugs, clinical research services, and sales of experimental animals and related products [1]. - For the first quarter of 2025, Zhaoyan New Drug reported revenue of 287 million yuan, a year-on-year decrease of 11.54%, while net profit reached 41.1195 million yuan, reflecting a year-on-year increase of 115.11%, with a gross profit margin of 28.61% [1]. Industry Summary - The average PE ratio for the medical services industry is 41.66 times, with a median of 43.69 times, placing Zhaoyan New Drug at the 29th position within the industry [1]. - As of the first quarter of 2025, 22 institutions held shares in Zhaoyan New Drug, including 20 funds, with a total holding of 72.9482 million shares valued at 1.484 billion yuan [1]. - The industry comparison shows that Zhaoyan New Drug's PE ratio is higher than the industry average but lower than the median, indicating a competitive yet challenging market position [2].

Core Viewpoint - The company, Zhaoyan New Drug, has experienced a stock price increase of 2.89% to 16.35 yuan, with a rolling PE ratio of 31.63, marking a new low in 16 days, and a total market capitalization of 12.254 billion yuan [1] Company Summary - Zhaoyan New Drug focuses on non-clinical safety evaluation services for drugs, preclinical research services, and sales of laboratory animals and related products [1] - The main products include non-clinical research services, clinical services, and experimental model supply [1] - As of the first quarter of 2025, the company reported revenue of 287 million yuan, a year-on-year decrease of 11.54%, and a net profit of 41.1195 million yuan, a year-on-year increase of 115.11%, with a gross profit margin of 28.61% [1] Industry Summary - The average PE ratio for the medical services industry is 38.86, with a median of 38.36, placing Zhaoyan New Drug at the 24th position within the industry [1] - As of the first quarter of 2025, 22 institutions hold shares in Zhaoyan New Drug, including 20 funds, with a total holding of 72.9482 million shares valued at 1.484 billion yuan [1]

Core Viewpoint - The company, Yinos, is a leading contract research organization (CRO) in the non-clinical safety evaluation sector, providing comprehensive research services that align with both domestic and international standards, and has recently passed a GLP inspection by the FDA, enhancing its international service capabilities [25][26]. Company Overview - Yinos specializes in non-clinical research services for biopharmaceuticals, being one of the earliest companies in China to obtain GLP certifications from NMPA, OECD, and FDA, thus aligning with international standards [3][4]. - The company has a modern facility of nearly 60,000 square meters and a research team of over 1,000, with locations in Shanghai, Nantong, Shenzhen, Huangshan, and San Francisco [4]. - As of December 31, 2024, Yinos has served over 900 pharmaceutical companies and research institutions, contributing to numerous successful drug development cases [4][18]. Financial Performance - In the reporting period, Yinos achieved a revenue of RMB 1,141.67 million, representing a year-on-year growth of 9.94%, while the net profit attributable to shareholders decreased by 24% to RMB 147.78 million [23]. - The proposed profit distribution plan includes a cash dividend of RMB 3.2 per 10 shares, totaling RMB 45.11 million, which accounts for 30.53% of the net profit for the year [1]. Industry Context - The global CRO market is projected to grow at a compound annual growth rate (CAGR) of 9.0% from 2023 to 2026, with the market size expected to exceed USD 147.7 billion by 2030 [11]. - In China, the CRO service market is estimated to reach RMB 848.2 billion in 2023, with a projected CAGR of 9.9% from 2023 to 2026 [12]. - The industry is supported by government policies aimed at enhancing drug research and development capabilities, which is expected to drive long-term growth in the CRO sector [13][14]. Technological Advancements - Yinos is investing in artificial intelligence (AI) applications in non-clinical research, aiming to enhance efficiency and reduce costs in drug development processes [19]. - The company is also exploring organoid technology for drug screening and toxicity testing, which is gaining traction in the pharmaceutical research field [19][20]. Strategic Positioning - Yinos has established strong partnerships with leading pharmaceutical companies, positioning itself as a strategic partner in the innovative drug development process [18][21]. - The company is expanding its international presence, having established a subsidiary in the United States to enhance its global market share [22].

本次股票发行后拟在科创板市场上市，科创板公司具有研发投入大、经营 风险高、业绩不稳定、退市风险高等特点，投资者面临较大的市场风险。投资 者应充分了解科创板的投资风险及本公司所披露的风险因素，审慎作出投资决 定。 科创板投资风险提示 上海益诺思生物技术股份有限公司 Shanghai InnoStar Bio-tech Co., Ltd. （中国（上海）自由贸易试验区郭守敬路 199 号 106 室） 首次公开发行股票并在科创板上市 招股说明书 （上会稿） 声明：本公司的发行申请尚需经上海证券交易所和中国证监会履行相应程 保荐机构（主承销商） （上海市广东路 689 号） 序。本招股说明书不具有据以发行股票的法律效力，仅供预先披露之用。 投资者应当以正式公告的招股说明书作为投资决定的依据。 上海益诺思生物技术股份有限公司 招股说明书（上会稿） 重要声明 | 发行股票类型 | 人民币普通股（A 股） | | --- | --- | | 发行股数 | 本次拟公开发行股票不超过 万股，不低于发行后总股 3,524.4904 | | | 本的 25%。 | | | 本次发行全部为新股发行，原股东不公开发售股份。 | | ...